Alpha2‐adrenergic agonist vs control: All‐cause mortality (within 30‐days after surgery: any reported death)
Alpha‐2 adrenergic agonists showed no clear difference in all‐cause mortality (within 30‐days after surgery: any reported death) compared with control (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Alpha‐2 adrenergic agonists vs control All‐cause mortality (within 30‐days after surgery: any reported death) · adults undergoing cardiac surgery Alpha‐2 adrenergic agonists showed no clear difference in all‐cause mortality (within 30‐days after surgery: any reported death) compared with control (moderate certainty). Alpha‐2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surgery (2018) · Cochrane Headline outcomes only | RR 0.52 [0.26, 1.04] | 16 studies · 1947 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Alpha‐2 adrenergic agonists for the prevention of cardiac complications among adults undergoing surgery 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.